HOLX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Hologic to Blackstone and TPG

Core Viewpoint - Wohl & Fruchter LLP is investigating the fairness of Hologic Inc.'s proposed sale to Blackstone and TPG for $76.00 per share in cash, along with a contingent value right (CVR) that could provide an additional $3.00 per share based on future revenue milestones [1][3][4] Group 1: Sale Details - Hologic has agreed to be sold for an upfront payment of $76.00 per share in cash, plus a non-tradeable CVR that could yield up to $3.00 per share if certain revenue targets are met post-closing [1][3] - The proposed sale price is below Hologic's 52-week high of $84.39 per share, leading to disappointment among several investors [2][3] Group 2: Investor Concerns - Investors have expressed concerns regarding the sale price, suggesting it should have been higher given the company's recent business re-acceleration and historical valuation standards [4] - Wohl & Fruchter LLP is examining whether Hologic's Board of Directors acted in the best interests of shareholders in approving the sale and if all material information about the transaction was disclosed [4]